Clinical Trials
909
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (835 trials with phase data)• Click on a phase to view related trials
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: JNJ-95298177
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT07082920
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Matching Placebo to UstekinumabDrug: Matching Placebo to JNJ-77242113
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 675
- Registration Number
- NCT06934226
- Locations
- 🇺🇸
Cahaba Research Inc, Birmingham, Alabama, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸T Joseph Raoof Md Inc, Encino, California, United States
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06919965
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT06881251
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸University of California Los Angeles - Division of Dermatology, Los Angeles, California, United States
🇺🇸Hamilton Research LLC, Alpharetta, Georgia, United States
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06878404
- Locations
- 🇺🇸
Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas, United States
🇺🇸Omega Research Consultants, DeBary, Florida, United States
🇺🇸Integral Rheumatology And Immunology Specialists, Plantation, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 178
- Next
News
Targeted Drug Combination Induces Remission in CLL Patients, Improving Survival and Quality of Life
A phase III clinical trial, FLAIR, demonstrated that a combination of venetoclax and ibrutinib is more effective than chemotherapy for chronic lymphocytic leukemia (CLL).